Related Experiment Videos
Severe hepatotoxicity on beginning propylthiouracil therapy
1Endocrinology Unit, Kaplan Hospital, Rehovot, Israel.
Journal of Clinical Gastroenterology
|June 1, 1997
Summary
Propylthiouracil (PTU) can cause liver damage in Graves' disease patients. Although liver abnormalities may persist for years, complete recovery from PTU-induced hepatotoxicity is possible.
Area of Science:
- Hepatology
- Endocrinology
- Pharmacology
Background:
- Graves' disease is an autoimmune disorder treated with antithyroid drugs.
- Propylthiouracil (PTU) is a common medication used to manage hyperthyroidism in Graves' disease.
- Drug-induced liver injury is a known, albeit rare, complication of PTU therapy.
Observation:
- A patient with Graves' disease developed cholestatic hepatotoxicity within one day of initiating PTU treatment.
- Clinical recovery was observed, but liver enzyme abnormalities persisted for five years post-treatment.
- Percutaneous liver biopsy and normalization of enzyme levels confirmed the absence of permanent liver damage.
Findings:
- Prolonged elevation of serum liver enzymes is indicative of PTU-induced hepatotoxicity.
- The liver injury in this case was severe and persistent, lasting for five years.
- Despite the prolonged duration, the liver damage was ultimately reversible.
Implications:
- This case highlights the potential for delayed and prolonged liver enzyme elevation following PTU-induced hepatotoxicity.
- It underscores the importance of monitoring liver function in patients receiving PTU, even after initial recovery.
- Complete resolution of PTU-induced liver injury is achievable, emphasizing the need for continued patient follow-up.